GLAND · Healthcare · Drug Manufacturers - Specialty & Generic
Composite scorecard: 49/100 — Quality 64 · Valuation 23 · Growth 32 · Momentum 85
| Share price | ₹2,459.10 |
| Market cap | ₹30,022 Cr |
| P/E ratio | 35.5 |
| P/B ratio | 3.1 |
| ROE | 9.7% |
| ROCE | 11.4% |
| Dividend yield | 0.99% |
| Book value | ₹580.47 |
| Year | Sales | Net profit | OPM |
|---|---|---|---|
| 2026 | ₹6,431 Cr | ₹1,027 Cr | 25.0% |
| 2025 | ₹5,616 Cr | ₹699 Cr | 23.0% |
| 2024 | ₹5,665 Cr | ₹772 Cr | 24.0% |
| 2023 | ₹3,625 Cr | ₹781 Cr | 28.0% |
| 2022 | ₹4,401 Cr | ₹1,212 Cr | 34.0% |
Gland Pharma Limited engages in manufacturing and sale of injectable formulations in India, the United States, Europe, Canada, Australia, New Zealand, and internationally. It engages in research and development of pharmaceutical active pharmaceutical ingredient products, including synthesis of complex drug molecules, such as low molecular weight heparins, corticosteroids, peptides, and cytotoxic molecules. The company also offers its products for various therapeutic categories, such as anti- diabetic, anti-malarial, anti-infectives, anti-neoplastic, blood related, cardiac, gastro-intestinal, g